Last updated: February 17, 2026
What is NDC 69102-0319?
NDC 69102-0319 is a biosimilar version of trastuzumab (Herceptin), used primarily in HER2-positive breast and gastric cancers. The drug is marketed under the brand "Kairuna," developed by a biosimilar manufacturer aiming to compete with the established reference product.
Market Overview
Patent Expiry and Market Entry
- Original trastuzumab patent expired in July 2018 in the U.S.
- Biosimilar entrants like NDC 69102-0319 entered the market starting in 2021.
- Biosimilar adoption depends on approval rates, payer acceptance, and clinician prescribing habits.
Market Size
- Global HER2-positive breast cancer market was valued at approximately $6.9 billion in 2022.
- The U.S. accounted for around 40% of this, roughly $2.76 billion.
- Biosimilars are projected to capture up to 60% of the HER2 market by 2025, driven by cost savings.
Reimbursement Landscape
- CMS and private payers favor biosimilars due to lower costs.
- Payer policies increasingly encourage biosimilar adoption for first-line therapy.
- Price discounts of 15-30% relative to reference trastuzumab are common, depending on negotiations.
Competitive Landscape
| Product |
Market Share (2022) |
Launch Year |
Price Discount |
Note |
| Herceptin (original) |
60% |
1998 |
— |
Largely replaced in new prescriptions by biosimilars |
| Kairuna (NDC 69102-0319) |
15% (est) |
2021 |
15-20% below Herceptin |
Growing market share, price stabilization needed |
| Other biosimilars (e.g., Herzuma, Ontruzant) |
25% |
2018-2019 |
20-30% below Herceptin |
Competitive pricing influences market shifts |
Key Competitors
- Herzuma (Celltrion/Teva)
- Ontruzant (Samsung Bioepis)
- Kairuna (market entrant)
Pricing Dynamics and Projections
Current Pricing (as of 2023)
- Brand: Approximately $6,500 per 440mg dose.
- Biosimilars: Roughly $5,000–$5,250 per 440mg dose, reflecting ~20% discount.
Pricing Trends
- Biosimilar prices vary based on contractual arrangements.
- Prices tend to decrease as more biosimilars enter the market, with discounts reaching 30% or more for volume contracts.
Price Projection 2024–2028
| Year |
Expected Average Price per 440mg Dose |
Key Factors |
| 2024 |
$4,750–$5,000 |
Increased biosimilar adoption, payer discounts, volume leverage |
| 2025 |
$4,500–$4,750 |
Market saturation, further biosimilar approvals |
| 2026 |
$4,250–$4,500 |
Patent expirations for other biosimilars, cost-based pricing |
| 2027 |
$4,000–$4,250 |
Cost reductions, increased biosimilar competition |
| 2028 |
$3,750–$4,000 |
Mature biosimilar market, standardization of pricing |
Market Risks
- Slow biosimilar adoption due to clinician preferences.
- Regulatory delays in biosimilar approval or reimbursement policies.
- Patent litigation extending market exclusivity of the reference product.
- Price erosion from emerging biosimilars and changing healthcare policies.
Key Takeaways
- NDC 69102-0319 competes in a mature biosimilar market with declining prices driven by increased competition.
- Biosimilars are expected to reduce the market price of trastuzumab by approximately 20–30% over the next 2–3 years.
- The overall HER2-positive breast cancer market remains sizable, with biosimilar penetration accelerating above 50% in the U.S. by 2025.
- Pricing strategies will be heavily influenced by payer negotiations, volume discounts, and regulatory developments.
Frequently Asked Questions
1. How does NDC 69102-0319 compare in efficacy to the reference trastuzumab?
Biosimilars like NDC 69102-0319 have demonstrated biosimilarity in analytical, preclinical, and clinical studies, with no meaningful differences in safety or efficacy compared to the reference product.
2. What factors influence biosimilar adoption in the oncology setting?
Physician prescribing habits, payer and hospital policies, cost savings, and physician familiarity significantly affect biosimilar uptake.
3. How might patent litigation affect the market for NDC 69102-0319?
Legal disputes can delay market entry or limit access, but patent expirations from 2018 onward have generally opened the market.
4. Are there upcoming biosimilar competitors for NDC 69102-0319?
Yes, additional biosimilars are in development or pending approval, potentially increasing price pressures over the next several years.
5. What is the outlook for biosimilar pricing in oncology therapeutics?
Prices will generally decline as biosimilars become standard practice, with discounts stabilizing around 20–30% relative to reference biologics.
References
- Evaluate Pharma, "Biosimilars Market Analysis," 2022.
- IQVIA, "U.S. Oncology Market Trends," 2022.
- U.S. FDA, Biosimilars Approval Data, 2023.
- CMS, "Hospital Outpatient PPS Final Rule," 2022.
- MarketResearch.com, "Global HER2-positive Breast Cancer Market," 2022.
